Summit Tx Capital, L.P. Verona Pharma PLC Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
A detailed history of Summit Tx Capital, L.P. transactions in Verona Pharma PLC stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 6,426 shares of VRNA stock, worth $586,501. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,426Holding current value
$586,501% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$599 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$504 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$358 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$316 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$264 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $5.56B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...